Table 3.

Course of liver enzymes in patients initially treated with D-penicillamine, grouped by treatment response

			Median UI/L (range)	P value
ALT (UI/L)	Baseline	Responder	201 (23–514)	.19
		Non-responder	398 (173–582)
	6 months	Responder	122 (32–576)	.26
		Non-responder	236 (165–279)
	12 months	Responder	60 (20–178)	≤.001
		Non-responder	91 (83–166)
	24 months	Responder	46 (14–76)	≤.001
		Non-responder	205 (65–245)
	>36 months	Responder	36 (12–77)	≤.001
		Non-responder	165 (91–377)
AST(UI/L)	Baseline	Responder	114 (27–227)	.24
		Non-responder	117 (72–205)
	6 months	Responder	60 (26–198)	.23
		Non-responder	94 (89–115)
	12 months	Responder	43 (22–74)	.18
		Non-responder	60 (47–60)
	24 months	Responder	38 (24–51)	≤.001
		Non-responder	100 (85–114)
	>36 months	Responder	32 (20–61)	.004
		Non-responder	66 (40–76)
GGT(UI/L)	Baseline	Responder	68 (11–227)	.54
		Non-responder	74 (48–267)
	6 months	Responder	39 (14–119)	.64
		Non-responder	59 (49–65)
	12 months	Responder	27 (13–57)	.19
		Non-responder	42 (36–48)
	24 months	Responder	24 (12–44)	.29
		Non-responder	31 (31–32)
	>36 months	Responder	17 (12–40)	.29
		Non-responder	31 (25–41)